文章核心观点 - 公司通过收购Ironshore Therapeutics公司,拓展了业务范围,进入了注意力缺陷多动障碍(ADHD)治疗领域,这是公司战略多元化的重要一步[4][5][6] - Jornay PM是一款具有差异化优势的ADHD治疗药物,预计2024年收入将超过1亿美元,是公司未来的主要增长动力[8] - 此次收购预计将立即提升公司的调整后EBITDA,并进一步增强公司的财务实力[6][9] 根据目录分别总结 交易概况 - 公司以5.25亿美元现金收购Ironshore公司,并有可能支付2500万美元的里程碑付款[9] - 交易资金来自公司现金和新增6.46亿美元的5年期贷款,利率较原贷款降低300个基点[9] - 交易预计将在2024年第三季度完成,需要获得必要的监管批准[10] 交易战略意义 - 拓展公司业务范围,进入ADHD这一大型且增长迅速的神经系统疾病治疗市场[6][8] - Jornay PM是一款具有差异化优势的ADHD治疗药物,有望成为公司的主要增长引擎[8] - 交易将提升公司的财务实力,预计将立即提升调整后EBITDA[6][9] 2024年二季度财务表现 - 公司2024年二季度产品净收入预计为1.45亿美元,同比增长7%[12] - 公司维持了2024年全年财务指引,包括产品收入、调整后营业费用和调整后EBITDA[13][14][15]

– Acquisition Funded by Collegium's Cash on Hand and New Five-Year Financing with Significantly Improved Terms – STOUGHTON, Mass. and GEORGE TOWN, Cayman Islands, July 29, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) and Ironshore Therapeutics Inc. today announced a definitive agreement pursuant to which Collegium will acquire Ironshore for $525 million in cash with the potential for an additional $25 million commercial milestone payment. Transaction Rationale Under the terms of th ...

"We are pleased with FDA's grant of pediatric exclusivity for the Nucynta Franchise," said Thomas Smith, M.D., Collegium's Chief Medical Officer. "This grant of pediatric exclusivity enhances the value of the Nucynta franchise and bolsters our near-term outlook. Collegium is proud to lead with science in support of people living with serious medical conditions and the communities we serve." Nucynta ER is currently approved in the U.S. for the management of severe and persistent pain in adults that requires ...

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Q1 2024 Results Conference Call May 9, 2024 4:30 PM ET Company Participants Christopher James - Vice President of Investor Relations Joe Ciaffoni - Chief Executive Officer Colleen Tupper - Chief Financial Officer Scott Dreyer - Chief Commercial Officer Mike Heffernan - Chairman Conference Call Participants David Amsellem - Piper Sandler Les Sulewski - Truist Securities Oren Livnat - H.C. Wainwright Operator Greetings. And welcome to the Collegium Pharmaceutical F ...

For the quarter ended March 2024, Collegium Pharmaceutical (COLL) reported revenue of $144.92 million, up 0.1% over the same period last year. EPS came in at $1.45, compared to $1.32 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $147.04 million, representing a surprise of -1.44%. The company delivered an EPS surprise of -2.68%, with the consensus EPS estimate being $1.49.While investors closely watch year-over-year changes in headline numbers -- revenue and earning ...

Collegium Pharmaceutical (COLL) came out with quarterly earnings of $1.45 per share, missing the Zacks Consensus Estimate of $1.49 per share. This compares to earnings of $1.32 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -2.68%. A quarter ago, it was expected that this specialty pharmaceutical company would post earnings of $1.33 per share when it actually produced earnings of $1.58, delivering a surprise of 18.80%.Over th ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37372 Collegium Pharmaceutical, Inc. (Exact name of registrant as specified in its charter) Virginia 03-04163 ...

Exhibit 99.1 Collegium Reports First Quarter 2024 Financial Results – Generated Q1’24 Net Revenue of $144.9 Million – – Delivered Q1’24 Record Belbuca® Revenue of $50.7 Million; Total Prescriptions Up 4.2% Year-over-Year – – Achieved Q1’24 GAAP Net Income of $27.7 Million vs. Q1’23 GAAP Net Loss of $(17.4) Million – – Delivered Q1’24 Adjusted EBITDA of $92.4 Million, Up 5% Year-over-Year – – Board of Directors Authorized $35.0 Million Accelerated Share Repurchase Program – – Reaffirmed Full-Year 2024 Guidan ...

– Joe Ciaffoni to Step Down as President and Chief Executive Officer – – Board Chairman Michael Heffernan to Serve as Interim President and Chief Executive Officer – – Board of Directors has Initiated the Search for a Successor – STOUGHTON, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that effective May 24, 2024, ...

Wall Street analysts forecast that Collegium Pharmaceutical (COLL) will report quarterly earnings of $1.49 per share in its upcoming release, pointing to a year-over-year increase of 12.9%. It is anticipated that revenues will amount to $147.04 million, exhibiting an increase of 1.6% compared to the year-ago quarter.Over the last 30 days, there has been a downward revision of 0.2% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective re ...